Neuromyelitis Optica Spectrum Disorder

Neurological Disorder MONDO:0019100 Pathograph 2 Autoimmune Disorder Demyelinating Disease

Ask OpenScientist

Ask a research question about Neuromyelitis Optica Spectrum Disorder. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

4
Pathophys.
5
Phenotypes
2
Pathograph
1
Genes
7
Treatments
3
Subtypes
18
References
2
Deep Research
◆

Subtypes

3
AQP4-IgG Seropositive NMOSD
The most common form, characterized by presence of antibodies against aquaporin-4 water channels on astrocytes. Associated with more severe attacks and higher relapse rates.
Show evidence (1 reference)
PMID:26092914 SUPPORT
"The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG)."
The 2015 international diagnostic criteria formally stratify NMOSD by AQP4-IgG serostatus.
MOG-IgG Associated Disease
Characterized by antibodies against myelin oligodendrocyte glycoprotein. Now recognized as a distinct entity (MOGAD) separate from AQP4+ NMOSD.
Show evidence (1 reference)
PMID:36706773 SUPPORT
"Serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG) are found in patients with acquired CNS demyelinating syndromes that are distinct from multiple sclerosis and aquaporin-4-seropositive neuromyelitis optica spectrum disorder."
International MOGAD criteria distinguish MOG-IgG-associated disease from AQP4-IgG-seropositive NMOSD.
Seronegative NMOSD
Meets clinical criteria for NMOSD but lacks detectable AQP4 or MOG antibodies.
Show evidence (1 reference)
PMID:26092914 SUPPORT
"More stringent clinical criteria, with additional neuroimaging findings, are required for diagnosis of NMOSD without AQP4-IgG or when serologic testing is unavailable."
The diagnostic consensus criteria explicitly define an AQP4-IgG-negative or untested NMOSD pathway.
⚙

Pathophysiology

4
Aquaporin-4 Autoimmunity
Anti-AQP4 (NMO-IgG) antibodies bind to aquaporin-4 water channels predominantly expressed on astrocyte end-feet at the blood-brain barrier. This initiates complement-dependent cytotoxicity leading to astrocyte death, secondary oligodendrocyte damage, demyelination, and neuronal injury.
astrocyte link
complement activation link
Show evidence (1 reference)
PMID:35454180 SUPPORT
"In NMOSD, the autoantibody (NMO-IgG) binds to the extracellular loops of AQP4 as expressed in perivascular astrocytic end-feet and disrupts astrocytes in a complement-dependent manner."
This review confirms that NMO-IgG binds AQP4 on astrocyte end-feet and causes complement-dependent astrocyte destruction.
Complement-Mediated Astrocyte Destruction
AQP4-IgG binding activates the classical complement cascade, leading to membrane attack complex formation and astrocyte lysis. This distinguishes NMOSD from MS where complement activation is less prominent.
complement activation, classical pathway link
Show evidence (1 reference)
PMID:31050279 SUPPORT
"At least two thirds of cases are associated with aquaporin-4 antibodies (AQP4-IgG) and complement-mediated damage to the central nervous system."
The PREVENT trial confirms that NMOSD involves complement-mediated CNS damage.
Blood-Brain Barrier Disruption
Inflammatory infiltrates including neutrophils, eosinophils, and macrophages cross the disrupted blood-brain barrier. Granulocyte infiltration is a hallmark feature distinguishing NMOSD lesions from MS plaques.
neutrophil link eosinophil link
blood brain barrier link
Show evidence (1 reference)
DOI:10.3390/app13085029 SUPPORT
"The autoantibodies against AQP4 target the AQP4 channel at the blood–brain barrier (BBB) of the astrocyte end feet, which leads to high permeability or leakage of the BBB that causes more influx of AQP4-antibodies into the cerebrospinal fluid (CSF) of NMO patients."
The review links AQP4 autoantibody binding at astrocytic blood-brain barrier end-feet to BBB leakage and antibody entry into CSF.
Secondary Demyelination
Unlike MS where oligodendrocytes are primary targets, in NMOSD demyelination occurs secondary to astrocyte loss. Loss of astrocyte trophic support leads to oligodendrocyte death and myelin breakdown.
oligodendrocyte link
myelination link ↓ DECREASED
myelin sheath link
Show evidence (2 references)
DOI:10.3390/app13085029 SUPPORT
"The binding of AQP4-IgG onto the AQP4 extracellular epitopes initiates astrocyte damage through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC)."
AQP4-IgG-driven astrocyte injury is upstream of the secondary tissue damage described in NMOSD lesions.
DOI:10.4103/nrr.nrr-d-23-01325 SUPPORT Model Organism
"These experimental models have successfully simulated many pathological features of neuromyelitis optica spectrum disorders, such as aquaporin-4 loss, astrocytopathy, granulocyte and macrophage infiltration, complement activation, demyelination, and neuronal loss"
AQP4-IgG models reproduce astrocytopathy together with demyelination, supporting demyelination as part of the downstream lesion cascade.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Neuromyelitis Optica Spectrum Disorder Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

5
Digestive 1
Area Postrema Syndrome FREQUENT Nausea and vomiting (HP:0002017)
Area postrema location: UBERON:0002162. This syndrome manifests clinically as the phenotype of nausea and vomiting due to inflammation of this specific brainstem structure.
Show evidence (1 reference)
PMID:26092914 SUPPORT
"The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema"
Area postrema syndrome is recognized as a core clinical feature of NMOSD.
Eye 1
Optic Neuritis VERY_FREQUENT Optic neuritis (HP:0100653)
Show evidence (1 reference)
PMID:26092914 SUPPORT
"The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations."
International diagnostic criteria identify optic nerve involvement as a core clinical characteristic of NMOSD.
Immune 1
Longitudinally Extensive Transverse Myelitis VERY_FREQUENT Myelitis (HP:0012486)
Extent: EXTENSIVE
HPO lacks a specific term for longitudinally extensive transverse myelitis, so the general HP:0012486 (Myelitis) is used together with the spatial_extent=EXTENSIVE qualifier (≥3 contiguous vertebral segments). A more specific preferred_term conveys the clinical concept.
Show evidence (1 reference)
PMID:26092914 SUPPORT
"The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema"
Spinal cord involvement (transverse myelitis) is a core diagnostic criterion.
Other 2
Acute Brainstem Syndrome OCCASIONAL
Show evidence (1 reference)
PMID:26092914 SUPPORT
"The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations."
International criteria include brainstem presentations among core NMOSD clinical characteristics.
Diencephalic Syndrome OCCASIONAL
Show evidence (1 reference)
PMID:26092914 SUPPORT
"The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations."
International criteria include diencephalic presentations among core NMOSD clinical characteristics.
🧬

Genetic Associations

1
HLA-DRB1*03:01 (Associated)
Show evidence (1 reference)
PMID:33420337 SUPPORT
"Neuromyelitis Optica patients have 2.46 more chances of having the DRB1*03 allelic group than controls. Ethnicity can influence genetic susceptibility. The main HLA association with Neuromyelitis Optica was the DRB1*03:01 allele in Western populations and with the DPB1*05:01 allele in Asia."
Meta-analysis confirms HLA-DRB1*03:01 as the primary genetic risk factor for NMO in Western populations, distinct from MS associations.
💊

Treatments

7
Acute Attack Treatment - Corticosteroids
Action: systemic corticosteroid therapy Ontology label: Systemic Corticosteroid Therapy NCIT:C122080
High-dose intravenous methylprednisolone (1g daily for 3-5 days) is first-line therapy for acute attacks.
Show evidence (1 reference)
DOI:10.3390/app13085029 SUPPORT
"Corticosteroids, apheresis therapies, immunosuppressive drugs, and B cell inactivating and complement cascade blocking agents have been used to treat NMOSD."
The review lists corticosteroids among therapies used for NMOSD.
Acute Attack Treatment - Plasma Exchange
Action: plasma exchange Ontology label: Plasmapheresis NCIT:C15304
Plasmapheresis is used for severe attacks unresponsive to steroids, removing pathogenic antibodies from circulation.
Show evidence (1 reference)
DOI:10.3390/app13085029 SUPPORT
"Corticosteroids, apheresis therapies, immunosuppressive drugs, and B cell inactivating and complement cascade blocking agents have been used to treat NMOSD."
The review identifies apheresis therapies, including plasma exchange, as NMOSD treatments.
Rituximab
Action: immunotherapy Ontology label: Immunotherapy NCIT:C15262
Agent: rituximab ↗
Anti-CD20 monoclonal antibody that depletes B cells. Widely used as maintenance therapy to prevent relapses.
Show evidence (1 reference)
PMID:35661568 SUPPORT
"Several studies have shown the efficacy of rituximab (RTX) in preventing relapses in patients suffering from Neuromyelitis Optica spectrum disorder (NMSOD) and have explored different therapeutic schemes."
This systematic review supports rituximab as relapse-prevention maintenance therapy in NMOSD.
Eculizumab
Action: complement inhibitor therapy Ontology label: complement 5 inhibitor agent therapy MAXO:0001483
Agent: eculizumab ↗
Complement C5 inhibitor approved for AQP4-positive NMOSD. Prevents complement-mediated astrocyte destruction by blocking terminal complement activation.
Show evidence (2 references)
PMID:31050279 SUPPORT
"Adjudicated relapses occurred in 3 of 96 patients (3%) in the eculizumab group and 20 of 47 (43%) in the placebo group"
The PREVENT trial demonstrated 94% reduction in relapse risk with eculizumab in AQP4-IgG-positive NMOSD.
PMID:32266705 SUPPORT
"The terminal complement protein (C5) inhibitor eculizumab (Soliris) is the first agent to be specifically approved in the EU, USA, Canada and Japan for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 water channel autoantibody (AQP4-IgG) seropositive"
Review confirms eculizumab as first approved targeted therapy for NMOSD.
Ravulizumab
Action: complement 5 inhibitor agent therapy MAXO:0001483
Agent: ravulizumab ↗
Long-acting complement C5 inhibitor used for relapse prevention in AQP4-IgG-positive NMOSD.
Mechanism Target:
INHIBITS Complement-Mediated Astrocyte Destruction — Terminal C5 blockade prevents formation of downstream complement effectors that mediate astrocyte injury after AQP4-IgG binding.
Show evidence (1 reference)
DOI:10.3389/fneur.2024.1332890 SUPPORT Human Clinical
"Immediate and complete terminal complement inhibition (free C5 serum concentrations < 0.5 μg/mL) was achieved by the end of the first ravulizumab infusion and sustained throughout the treatment period."
Pharmacodynamic data in AQP4-IgG-positive NMOSD directly support ravulizumab inhibition of terminal C5 activity, the mechanism targeted by this treatment.
Show evidence (1 reference)
DOI:10.1017/cjn.2024.119 SUPPORT Human Clinical
"Ravulizumab demonstrated long-term clinical benefit in the prevention of relapses in AQP4+ NMOSD with a safety profile consistent with prior analyses."
Phase 3 CHAMPION-NMOSD interim results support ravulizumab as a mechanism-matched relapse-prevention therapy for AQP4-IgG-positive NMOSD.
Inebilizumab
Action: biologic therapy Ontology label: Immunotherapy NCIT:C15262
Agent: inebilizumab ↗
Anti-CD19 monoclonal antibody approved for AQP4-positive NMOSD. Provides broader B cell depletion than rituximab by targeting CD19.
Show evidence (2 references)
PMID:31495497 SUPPORT
"21 (12%) of 174 participants receiving inebilizumab had an attack versus 22 (39%) of 56 participants receiving placebo"
The N-MOmentum trial demonstrated 73% reduction in attack risk with inebilizumab treatment.
PMID:36070074 SUPPORT
"Inebilizumab (Uplizna) is a recently approved monoclonal antibody for use in adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody seropositive."
Review confirms regulatory approval of inebilizumab for NMOSD.
Satralizumab
Action: biologic therapy Ontology label: Immunotherapy NCIT:C15262
Agent: satralizumab ↗
IL-6 receptor inhibitor approved for AQP4-positive NMOSD. IL-6 promotes plasmablast survival and antibody production.
Show evidence (1 reference)
PMID:36933107 SUPPORT
"Satralizumab (Enspryng) is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor and is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in patients who are aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive."
Review confirms satralizumab mechanism and approval for NMOSD.
{ }

Source YAML

click to show 
name: Neuromyelitis Optica Spectrum Disorder
creation_date: '2026-01-15T00:00:04Z'
updated_date: '2026-05-17T05:55:13Z'
category: Neurological Disorder
parents:
- Autoimmune Disorder
- Demyelinating Disease
disease_term:
  preferred_term: neuromyelitis optica spectrum disorder
  term:
    id: MONDO:0019100
    label: neuromyelitis optica
has_subtypes:
- name: AQP4-IgG Seropositive NMOSD
  description: >
    The most common form, characterized by presence of antibodies against
    aquaporin-4 water channels on astrocytes. Associated with more severe
    attacks and higher relapse rates.
  evidence:
  - reference: PMID:26092914
    reference_title: "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders."
    supports: SUPPORT
    snippet: >-
      The new nomenclature defines the unifying term NMO spectrum disorders
      (NMOSD), which is stratified further by serologic testing (NMOSD with
      or without AQP4-IgG).
    explanation: >-
      The 2015 international diagnostic criteria formally stratify NMOSD
      by AQP4-IgG serostatus.
- name: MOG-IgG Associated Disease
  description: >
    Characterized by antibodies against myelin oligodendrocyte glycoprotein.
    Now recognized as a distinct entity (MOGAD) separate from AQP4+ NMOSD.
  evidence:
  - reference: PMID:36706773
    reference_title: "Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria."
    supports: SUPPORT
    snippet: >-
      Serum antibodies directed against myelin oligodendrocyte glycoprotein
      (MOG) are found in patients with acquired CNS demyelinating syndromes
      that are distinct from multiple sclerosis and aquaporin-4-seropositive
      neuromyelitis optica spectrum disorder.
    explanation: >-
      International MOGAD criteria distinguish MOG-IgG-associated disease from
      AQP4-IgG-seropositive NMOSD.
- name: Seronegative NMOSD
  description: >
    Meets clinical criteria for NMOSD but lacks detectable AQP4 or MOG antibodies.
  evidence:
  - reference: PMID:26092914
    reference_title: "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders."
    supports: SUPPORT
    snippet: >-
      More stringent clinical criteria, with additional neuroimaging findings,
      are required for diagnosis of NMOSD without AQP4-IgG or when serologic
      testing is unavailable.
    explanation: >-
      The diagnostic consensus criteria explicitly define an AQP4-IgG-negative
      or untested NMOSD pathway.
pathophysiology:
- name: Aquaporin-4 Autoimmunity
  description: >
    Anti-AQP4 (NMO-IgG) antibodies bind to aquaporin-4 water channels
    predominantly expressed on astrocyte end-feet at the blood-brain barrier.
    This initiates complement-dependent cytotoxicity leading to astrocyte death,
    secondary oligodendrocyte damage, demyelination, and neuronal injury.
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
  evidence:
  - reference: PMID:35454180
    reference_title: "Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System."
    supports: SUPPORT
    snippet: >-
      In NMOSD, the autoantibody (NMO-IgG) binds to the extracellular loops
      of AQP4 as expressed in perivascular astrocytic end-feet and disrupts
      astrocytes in a complement-dependent manner.
    explanation: >-
      This review confirms that NMO-IgG binds AQP4 on astrocyte end-feet and
      causes complement-dependent astrocyte destruction.
- name: Complement-Mediated Astrocyte Destruction
  description: >
    AQP4-IgG binding activates the classical complement cascade, leading to
    membrane attack complex formation and astrocyte lysis. This distinguishes
    NMOSD from MS where complement activation is less prominent.
  biological_processes:
  - preferred_term: complement activation, classical pathway
    term:
      id: GO:0006958
      label: complement activation, classical pathway
  evidence:
  - reference: PMID:31050279
    reference_title: "Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder."
    supports: SUPPORT
    snippet: >-
      At least two thirds of cases are associated with aquaporin-4 antibodies
      (AQP4-IgG) and complement-mediated damage to the central nervous system.
    explanation: >-
      The PREVENT trial confirms that NMOSD involves complement-mediated CNS damage.
- name: Blood-Brain Barrier Disruption
  description: >
    Inflammatory infiltrates including neutrophils, eosinophils, and macrophages
    cross the disrupted blood-brain barrier. Granulocyte infiltration is a
    hallmark feature distinguishing NMOSD lesions from MS plaques.
  locations:
  - preferred_term: blood brain barrier
    term:
      id: UBERON:0000120
      label: blood brain barrier
  cell_types:
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  - preferred_term: eosinophil
    term:
      id: CL:0000771
      label: eosinophil
  evidence:
  - reference: DOI:10.3390/app13085029
    reference_title: 'Neuromyelitis Optica Spectrum Disorders: Clinical Perspectives, Molecular Mechanisms, and Treatments'
    supports: SUPPORT
    snippet: >-
      The autoantibodies against AQP4 target the AQP4 channel at the
      blood–brain barrier (BBB) of the astrocyte end feet, which leads to high
      permeability or leakage of the BBB that causes more influx of
      AQP4-antibodies into the cerebrospinal fluid (CSF) of NMO patients.
    explanation: >-
      The review links AQP4 autoantibody binding at astrocytic blood-brain
      barrier end-feet to BBB leakage and antibody entry into CSF.
- name: Secondary Demyelination
  description: >
    Unlike MS where oligodendrocytes are primary targets, in NMOSD demyelination
    occurs secondary to astrocyte loss. Loss of astrocyte trophic support leads
    to oligodendrocyte death and myelin breakdown.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: myelination
    modifier: DECREASED
    term:
      id: GO:0042552
      label: myelination
  cellular_components:
  - preferred_term: myelin sheath
    term:
      id: GO:0043209
      label: myelin sheath
  evidence:
  - reference: DOI:10.3390/app13085029
    reference_title: 'Neuromyelitis Optica Spectrum Disorders: Clinical Perspectives, Molecular Mechanisms, and Treatments'
    supports: SUPPORT
    snippet: >-
      The binding of AQP4-IgG onto the AQP4 extracellular epitopes initiates
      astrocyte damage through complement-dependent cytotoxicity (CDC) and
      antibody-dependent cellular cytotoxicity (ADCC).
    explanation: >-
      AQP4-IgG-driven astrocyte injury is upstream of the secondary tissue damage
      described in NMOSD lesions.
  - reference: DOI:10.4103/nrr.nrr-d-23-01325
    reference_title: 'Aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress of experimental models based on disease pathogenesis'
    evidence_source: MODEL_ORGANISM
    supports: SUPPORT
    snippet: >-
      These experimental models have successfully simulated many pathological
      features of neuromyelitis optica spectrum disorders, such as aquaporin-4
      loss, astrocytopathy, granulocyte and macrophage infiltration, complement
      activation, demyelination, and neuronal loss
    explanation: >-
      AQP4-IgG models reproduce astrocytopathy together with demyelination,
      supporting demyelination as part of the downstream lesion cascade.
phenotypes:
- name: Optic Neuritis
  description: >
    Inflammation of the optic nerve causing acute vision loss, eye pain,
    and color vision impairment. Often bilateral and severe in NMOSD
    compared to MS-associated optic neuritis.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: optic neuritis
    term:
      id: HP:0100653
      label: Optic neuritis
  evidence:
  - reference: PMID:26092914
    reference_title: "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders."
    supports: SUPPORT
    snippet: >-
      The core clinical characteristics required for patients with NMOSD with
      AQP4-IgG include clinical syndromes or MRI findings related to optic nerve,
      spinal cord, area postrema, other brainstem, diencephalic, or cerebral
      presentations.
    explanation: >-
      International diagnostic criteria identify optic nerve involvement as a
      core clinical characteristic of NMOSD.
- name: Longitudinally Extensive Transverse Myelitis
  description: >
    Longitudinally extensive transverse myelitis (LETM) affecting three or more
    vertebral segments is characteristic of NMOSD, distinguishing it from the
    shorter lesions typical of multiple sclerosis. Causes paraplegia, sensory
    loss, and bladder/bowel dysfunction. LETM is a core diagnostic criterion
    for NMOSD.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: longitudinally extensive transverse myelitis
    term:
      id: HP:0012486
      label: Myelitis
    spatial_extent: EXTENSIVE
  notes: >
    HPO lacks a specific term for longitudinally extensive transverse myelitis,
    so the general HP:0012486 (Myelitis) is used together with the
    spatial_extent=EXTENSIVE qualifier (≥3 contiguous vertebral segments).
    A more specific preferred_term conveys the clinical concept.
  evidence:
  - reference: PMID:26092914
    reference_title: "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders."
    supports: SUPPORT
    snippet: >-
      The core clinical characteristics required for patients with NMOSD with
      AQP4-IgG include clinical syndromes or MRI findings related to optic nerve,
      spinal cord, area postrema
    explanation: >-
      Spinal cord involvement (transverse myelitis) is a core diagnostic criterion.
- name: Area Postrema Syndrome
  description: >
    Intractable nausea, vomiting, and hiccups due to inflammation of the
    area postrema (UBERON:0002162) in the dorsal medulla. A characteristic
    early manifestation that may precede other symptoms. This is a syndrome
    involving a specific anatomical location rather than a simple phenotype.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: intractable nausea and vomiting
    term:
      id: HP:0002017
      label: Nausea and vomiting
  notes: >
    Area postrema location: UBERON:0002162. This syndrome manifests clinically
    as the phenotype of nausea and vomiting due to inflammation of this specific
    brainstem structure.
  evidence:
  - reference: PMID:26092914
    reference_title: "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders."
    supports: SUPPORT
    snippet: >-
      The core clinical characteristics required for patients with NMOSD with
      AQP4-IgG include clinical syndromes or MRI findings related to optic nerve,
      spinal cord, area postrema
    explanation: >-
      Area postrema syndrome is recognized as a core clinical feature of NMOSD.
- name: Acute Brainstem Syndrome
  description: >
    Involvement of brainstem structures causing diplopia, facial weakness,
    dysphagia, and respiratory failure in severe cases.
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:26092914
    reference_title: "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders."
    supports: SUPPORT
    snippet: >-
      The core clinical characteristics required for patients with NMOSD with
      AQP4-IgG include clinical syndromes or MRI findings related to optic nerve,
      spinal cord, area postrema, other brainstem, diencephalic, or cerebral
      presentations.
    explanation: >-
      International criteria include brainstem presentations among core NMOSD
      clinical characteristics.
- name: Diencephalic Syndrome
  description: >
    Hypothalamic involvement causing narcolepsy-like symptoms, endocrine
    dysfunction, and syndrome of inappropriate ADH secretion.
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:26092914
    reference_title: "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders."
    supports: SUPPORT
    snippet: >-
      The core clinical characteristics required for patients with NMOSD with
      AQP4-IgG include clinical syndromes or MRI findings related to optic nerve,
      spinal cord, area postrema, other brainstem, diencephalic, or cerebral
      presentations.
    explanation: >-
      International criteria include diencephalic presentations among core
      NMOSD clinical characteristics.
genetic:
- name: HLA-DRB1*03:01
  association: Associated
  notes: >
    Strong genetic association with HLA class II alleles, particularly
    HLA-DRB1*03:01, suggesting T cell involvement in disease initiation.
    This distinguishes NMOSD from MS which is associated with HLA-DRB1*15.
  evidence:
  - reference: PMID:33420337
    reference_title: "Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis: a systematic review with meta-analysis."
    supports: SUPPORT
    snippet: >-
      Neuromyelitis Optica patients have 2.46 more chances of having the DRB1*03
      allelic group than controls. Ethnicity can influence genetic susceptibility.
      The main HLA association with Neuromyelitis Optica was the DRB1*03:01 allele
      in Western populations and with the DPB1*05:01 allele in Asia.
    explanation: >-
      Meta-analysis confirms HLA-DRB1*03:01 as the primary genetic risk factor
      for NMO in Western populations, distinct from MS associations.
treatments:
- name: Acute Attack Treatment - Corticosteroids
  description: >
    High-dose intravenous methylprednisolone (1g daily for 3-5 days) is
    first-line therapy for acute attacks.
  treatment_term:
    preferred_term: systemic corticosteroid therapy
    term:
      id: NCIT:C122080
      label: Systemic Corticosteroid Therapy
  evidence:
  - reference: DOI:10.3390/app13085029
    reference_title: 'Neuromyelitis Optica Spectrum Disorders: Clinical Perspectives, Molecular Mechanisms, and Treatments'
    supports: SUPPORT
    snippet: >-
      Corticosteroids, apheresis therapies, immunosuppressive drugs, and B cell
      inactivating and complement cascade blocking agents have been used to
      treat NMOSD.
    explanation: >-
      The review lists corticosteroids among therapies used for NMOSD.
- name: Acute Attack Treatment - Plasma Exchange
  description: >
    Plasmapheresis is used for severe attacks unresponsive to steroids,
    removing pathogenic antibodies from circulation.
  treatment_term:
    preferred_term: plasma exchange
    term:
      id: NCIT:C15304
      label: Plasmapheresis
  evidence:
  - reference: DOI:10.3390/app13085029
    reference_title: 'Neuromyelitis Optica Spectrum Disorders: Clinical Perspectives, Molecular Mechanisms, and Treatments'
    supports: SUPPORT
    snippet: >-
      Corticosteroids, apheresis therapies, immunosuppressive drugs, and B cell
      inactivating and complement cascade blocking agents have been used to
      treat NMOSD.
    explanation: >-
      The review identifies apheresis therapies, including plasma exchange, as
      NMOSD treatments.
- name: Rituximab
  description: >
    Anti-CD20 monoclonal antibody that depletes B cells. Widely used as
    maintenance therapy to prevent relapses.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
  evidence:
  - reference: PMID:35661568
    reference_title: "Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: A systematic review."
    supports: SUPPORT
    snippet: >-
      Several studies have shown the efficacy of rituximab (RTX) in preventing
      relapses in patients suffering from Neuromyelitis Optica spectrum disorder
      (NMSOD) and have explored different therapeutic schemes.
    explanation: >-
      This systematic review supports rituximab as relapse-prevention maintenance
      therapy in NMOSD.
- name: Eculizumab
  description: >
    Complement C5 inhibitor approved for AQP4-positive NMOSD. Prevents
    complement-mediated astrocyte destruction by blocking terminal
    complement activation.
  treatment_term:
    preferred_term: complement inhibitor therapy
    term:
      id: MAXO:0001483
      label: complement 5 inhibitor agent therapy
    therapeutic_agent:
    - preferred_term: eculizumab
      term:
        id: NCIT:C48386
        label: Eculizumab
  evidence:
  - reference: PMID:31050279
    reference_title: "Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder."
    supports: SUPPORT
    snippet: >-
      Adjudicated relapses occurred in 3 of 96 patients (3%) in the eculizumab
      group and 20 of 47 (43%) in the placebo group
    explanation: >-
      The PREVENT trial demonstrated 94% reduction in relapse risk with
      eculizumab in AQP4-IgG-positive NMOSD.
  - reference: PMID:32266705
    reference_title: "Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder."
    supports: SUPPORT
    snippet: >-
      The terminal complement protein (C5) inhibitor eculizumab (Soliris) is the
      first agent to be specifically approved in the EU, USA, Canada and Japan for
      the
      treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are
      aquaporin-4 water channel autoantibody (AQP4-IgG) seropositive
    explanation: >-
      Review confirms eculizumab as first approved targeted therapy for NMOSD.
- name: Ravulizumab
  description: >
    Long-acting complement C5 inhibitor used for relapse prevention in
    AQP4-IgG-positive NMOSD.
  treatment_term:
    preferred_term: complement 5 inhibitor agent therapy
    term:
      id: MAXO:0001483
      label: complement 5 inhibitor agent therapy
    therapeutic_agent:
    - preferred_term: ravulizumab
      term:
        id: NCIT:C124657
        label: Ravulizumab
  target_mechanisms:
  - target: Complement-Mediated Astrocyte Destruction
    treatment_effect: INHIBITS
    description: >
      Terminal C5 blockade prevents formation of downstream complement effectors
      that mediate astrocyte injury after AQP4-IgG binding.
    evidence:
    - reference: DOI:10.3389/fneur.2024.1332890
      reference_title: Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Immediate and complete terminal complement inhibition (free C5 serum
        concentrations < 0.5 μg/mL) was achieved by the end of the first
        ravulizumab infusion and sustained throughout the treatment period.
      explanation: >-
        Pharmacodynamic data in AQP4-IgG-positive NMOSD directly support
        ravulizumab inhibition of terminal C5 activity, the mechanism targeted by
        this treatment.
  evidence:
  - reference: DOI:10.1017/cjn.2024.119
    reference_title: 'P.011 Efficacy and safety of ravulizumab in adults with AQP4+ NMOSD: interim analysis from the ongoing phase 3 CHAMPION-NMOSD trial'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ravulizumab demonstrated long-term clinical benefit in the prevention of
      relapses in AQP4+ NMOSD with a safety profile consistent with prior
      analyses.
    explanation: >-
      Phase 3 CHAMPION-NMOSD interim results support ravulizumab as a
      mechanism-matched relapse-prevention therapy for AQP4-IgG-positive NMOSD.
- name: Inebilizumab
  description: >
    Anti-CD19 monoclonal antibody approved for AQP4-positive NMOSD.
    Provides broader B cell depletion than rituximab by targeting CD19.
  treatment_term:
    preferred_term: biologic therapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: inebilizumab
      term:
        id: NCIT:C88283
        label: Inebilizumab
  evidence:
  - reference: PMID:31495497
    reference_title: "Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial."
    supports: SUPPORT
    snippet: >-
      21 (12%) of 174 participants receiving inebilizumab had an attack versus
      22 (39%) of 56 participants receiving placebo
    explanation: >-
      The N-MOmentum trial demonstrated 73% reduction in attack risk with
      inebilizumab treatment.
  - reference: PMID:36070074
    reference_title: "Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder."
    supports: SUPPORT
    snippet: >-
      Inebilizumab (Uplizna) is a recently approved monoclonal antibody for use in
      adults with neuromyelitis optica spectrum disorder (NMOSD) who are
      anti-aquaporin-4 (AQP4) antibody seropositive.
    explanation: >-
      Review confirms regulatory approval of inebilizumab for NMOSD.
- name: Satralizumab
  description: >
    IL-6 receptor inhibitor approved for AQP4-positive NMOSD. IL-6
    promotes plasmablast survival and antibody production.
  treatment_term:
    preferred_term: biologic therapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: satralizumab
      term:
        id: NCIT:C152307
        label: Satralizumab
  evidence:
  - reference: PMID:36933107
    reference_title: "Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder."
    supports: SUPPORT
    snippet: >-
      Satralizumab (Enspryng) is a monoclonal antibody that blocks the
      interleukin-6 (IL-6) receptor and is approved for the treatment of
      neuromyelitis optica spectrum disorder (NMOSD) in patients who are
      aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive.
    explanation: >-
      Review confirms satralizumab mechanism and approval for NMOSD.
datasets:
references:
- reference: DOI:10.1017/cjn.2024.119
  title: 'P.011 Efficacy and safety of ravulizumab in adults with AQP4+ NMOSD: interim analysis from the ongoing phase 3 CHAMPION-NMOSD trial'
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
- reference: DOI:10.1038/s41598-024-53661-5
  title: Anti-aquaporin-4 immune complex stimulates complement-dependent Th17 cytokine release in neuromyelitis optica spectrum disorders
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-cyberian-codex.md
  findings: []
- reference: DOI:10.1056/nejmoa1900866
  title: Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
- reference: DOI:10.1097/wno.0000000000000396
  title: 'Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica'
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
- reference: DOI:10.1136/jnnp-2022-330412
  title: 'Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder'
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
- reference: DOI:10.1177/13524585231224683
  title: Prevalence of neuromyelitis optica spectrum disorder in the United States
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
- reference: DOI:10.1177/17562864231181177
  title: 'Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan'
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
- reference: DOI:10.1212/wnl.0000000000001729
  title: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
- reference: DOI:10.14312/2397-1304.2015-2
  title: 'Neuromyelitis optica spectrum disorders with and without aquaporin 4 antibody: Characterization, differential diagnosis, and recent advances'
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
- reference: DOI:10.2217/nmt-2020-0046
  title: Satralizumab in the Treatment of Neuromyelitis Optica Spectrum Disorder
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
- reference: DOI:10.3389/fimmu.2024.1423107
  title: Scientific issues with rodent models of neuromyelitis optic spectrum disorders
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
- reference: DOI:10.3389/fneur.2024.1332890
  title: Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
- reference: DOI:10.3389/fneur.2024.1415535
  title: 'Soluble biomarkers for Neuromyelitis Optica Spectrum Disorders: a mini review'
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/app13085029
  title: 'Neuromyelitis Optica Spectrum Disorders: Clinical Perspectives, Molecular Mechanisms, and Treatments'
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/ijms25063179
  title: The Role of Gut Microbiota in Neuromyelitis Optica Spectrum Disorder
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/ijms251910625
  title: Blood–Brain Barrier Disruption in Neuroimmunological Disease
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-cyberian-codex.md
  findings: []
- reference: DOI:10.3390/medicina60071050
  title: 'The Role of Glial Fibrillary Acidic Protein as a Biomarker in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis'
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
- reference: DOI:10.4103/nrr.nrr-d-23-01325
  title: 'Aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress of experimental models based on disease pathogenesis'
  found_in:
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-cyberian-codex.md
  - Neuromyelitis_Optica_Spectrum_Disorder-deep-research-falcon.md
  findings: []
📚

References & Deep Research

References

18
DOI:10.1017/cjn.2024.119
P.011 Efficacy and safety of ravulizumab in adults with AQP4+ NMOSD: interim analysis from the ongoing phase 3 CHAMPION-NMOSD trial
No top-level findings curated for this source.
DOI:10.1038/s41598-024-53661-5
Anti-aquaporin-4 immune complex stimulates complement-dependent Th17 cytokine release in neuromyelitis optica spectrum disorders
No top-level findings curated for this source.
DOI:10.1056/nejmoa1900866
Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
No top-level findings curated for this source.
DOI:10.1097/wno.0000000000000396
Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica
No top-level findings curated for this source.
DOI:10.1136/jnnp-2022-330412
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder
No top-level findings curated for this source.
DOI:10.1177/13524585231224683
Prevalence of neuromyelitis optica spectrum disorder in the United States
No top-level findings curated for this source.
DOI:10.1177/17562864231181177
Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan
No top-level findings curated for this source.
DOI:10.1212/wnl.0000000000001729
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
No top-level findings curated for this source.
DOI:10.14312/2397-1304.2015-2
Neuromyelitis optica spectrum disorders with and without aquaporin 4 antibody: Characterization, differential diagnosis, and recent advances
No top-level findings curated for this source.
DOI:10.2217/nmt-2020-0046
Satralizumab in the Treatment of Neuromyelitis Optica Spectrum Disorder
No top-level findings curated for this source.
DOI:10.3389/fimmu.2024.1423107
Scientific issues with rodent models of neuromyelitis optic spectrum disorders
No top-level findings curated for this source.
DOI:10.3389/fneur.2024.1332890
Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
No top-level findings curated for this source.
DOI:10.3389/fneur.2024.1415535
Soluble biomarkers for Neuromyelitis Optica Spectrum Disorders: a mini review
No top-level findings curated for this source.
DOI:10.3390/app13085029
Neuromyelitis Optica Spectrum Disorders: Clinical Perspectives, Molecular Mechanisms, and Treatments
No top-level findings curated for this source.
DOI:10.3390/ijms25063179
The Role of Gut Microbiota in Neuromyelitis Optica Spectrum Disorder
No top-level findings curated for this source.
DOI:10.3390/ijms251910625
Blood–Brain Barrier Disruption in Neuroimmunological Disease
No top-level findings curated for this source.
DOI:10.3390/medicina60071050
The Role of Glial Fibrillary Acidic Protein as a Biomarker in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis
No top-level findings curated for this source.
DOI:10.4103/nrr.nrr-d-23-01325
Aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress of experimental models based on disease pathogenesis
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Neuromyelitis Optica Spectrum Disorder
  • Category: Neurological Disorder
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 15

Key Pathophysiology Nodes

  • Aquaporin-4 Autoimmunity
  • Complement-Mediated Astrocyte Destruction
  • Blood-Brain Barrier Disruption
  • Secondary Demyelination
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1038/s41598-024-53661-5
  • DOI:10.3390/ijms251910625
  • DOI:10.4103/nrr.nrr-d-23-01325
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 48 citations 2026-04-23T18:52:34.920735

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Neuromyelitis Optica Spectrum Disorder
  • MONDO ID: (if available)
  • Category: Neurological Disorder

Research Objectives

Please provide a comprehensive research report on Neuromyelitis Optica Spectrum Disorder covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Neuromyelitis Optica Spectrum Disorder (NMOSD): Comprehensive Disease Characteristics Report (2023–2024 Emphasis)

Executive summary

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, predominantly relapsing autoimmune inflammatory disorder of the central nervous system (CNS) that classically affects the optic nerves and spinal cord and is frequently associated with pathogenic aquaporin-4 immunoglobulin G (AQP4-IgG) autoantibodies. Consensus diagnostic criteria (IPND 2015) stratify diagnosis by AQP4-IgG serostatus and define six “core clinical characteristics.” Major recent developments include broad implementation of cell-based AQP4-IgG assays, biomarker work (serum GFAP and neurofilament light chain), and multiple targeted relapse-prevention therapies with high-level clinical trial evidence (C5 complement inhibitors, IL-6 receptor blockade) plus real-world post-marketing surveillance data. (wingerchuk2015internationalconsensusdiagnostic pages 3-3, rodin2024solublebiomarkersfor pages 1-2)

Evidence domain Source (year) Journal URL Key findings Citation
Diagnostic criteria / identifiers Wingerchuk et al. (2015) Neurology https://doi.org/10.1212/WNL.0000000000001729 IPND 2015 unified the term NMOSD and stratified diagnosis by AQP4-IgG status. AQP4-IgG-positive: ≥1 core clinical characteristic + positive AQP4-IgG (best available assay) + exclusion of alternatives. AQP4-IgG-negative/unknown: ≥2 core clinical characteristics from ≥1 attacks, with ≥1 being optic neuritis, acute myelitis with LETM, or area postrema syndrome; dissemination in space; additional MRI requirements; exclusion of alternatives. Six core characteristics: optic neuritis, acute myelitis, area postrema syndrome, acute brainstem syndrome, symptomatic narcolepsy/acute diencephalic syndrome with typical MRI lesions, symptomatic cerebral syndrome with typical lesions. (bennett2016findingnmothe pages 11-12, wingerchuk2015internationalconsensusdiagnostic pages 3-3, wingerchuk2015internationalconsensusdiagnostic pages 2-3)
Epidemiology Briggs & Shaia (2024) Multiple Sclerosis Journal https://doi.org/10.1177/13524585231224683 2022 U.S. EHR-based prevalence: 6.88/100,000 (1,772 NMOSD patients among 25,743,039). By race: Black 12.99/100,000, Asian 9.41/100,000, White 5.58/100,000. By sex: female 9.48/100,000, male 3.52/100,000; observed female:male ratio 3.5:1. Estimated ~22,000 Americans living with NMOSD in 2022; 15,413 females and 6,233 males. (briggs2024prevalenceofneuromyelitis pages 1-3, briggs2024prevalenceofneuromyelitis media c3f20c73)
Eculizumab pivotal trial (PREVENT) Pittock et al. (2019) New England Journal of Medicine https://doi.org/10.1056/NEJMoa1900866 In AQP4-IgG-positive NMOSD, adjudicated relapses occurred in 3/96 (3%) on eculizumab vs 20/47 (43%) on placebo; hazard ratio 0.06 (95% CI 0.02–0.20; P<0.001). Adjudicated annualized relapse rate: 0.02 vs 0.35. Baseline annualized relapse rate over prior 24 months: 1.99±0.94. (pittock2019eculizumabinaquaporin4–positive pages 4-5)
Eculizumab real-world implementation Nakashima et al. (2023) Therapeutic Advances in Neurological Disorders https://doi.org/10.1177/17562864231181177 Japan post-marketing surveillance: safety set 71; effectiveness set 68; 94.4% female; mean age at initiation 50.7 years. Relapse rate decreased from 0.74/patient-year in the 2 years pre-eculizumab to 0.02/patient-year after initiation. Adverse events in 19/71 (26.8%); adverse drug reactions 10/71 (14.1%); serious ADRs 7/71 (9.9%); no meningococcal infections reported. (nakashima2023longtermsafetyand pages 1-2)
Ravulizumab phase 3 Pittock et al. (2024) Canadian Journal of Neurological Sciences https://doi.org/10.1017/cjn.2024.119 CHAMPION-NMOSD interim analysis: 58 patients; median follow-up 138.4 weeks (range 11.0–183.1), 153.9 patient-years. No adjudicated on-trial relapses across primary treatment period and long-term extension. 91.4% (53/58) had stable/improved Hauser Ambulation Index; 91.4% (53/58) had no clinically important EDSS worsening. TEAEs 94.8%; serious AEs 25.9%; withdrawal due to TEAE in 1 patient. (pittock2024p.011efficacyand pages 1-1)
Ravulizumab PK/PD Ortiz et al. (2024) Frontiers in Neurology https://doi.org/10.3389/fneur.2024.1332890 In 58 treated AQP4+ NMOSD patients, ravulizumab achieved serum concentrations above therapeutic threshold (≥175 μg/mL) in all patients after first dose and maintained for 50 weeks. Immediate and complete terminal complement inhibition achieved by end of first infusion: free C5 <0.5 μg/mL throughout treatment. Week-50 mean Cmax 1,887.6 μg/mL, mean Ctrough 764.4 μg/mL. (ortiz2024immediateandsustained pages 1-2)
Biomarker trial analysis / inebilizumab Aktas et al. (2023) Journal of Neurology, Neurosurgery & Psychiatry https://doi.org/10.1136/jnnp-2022-330412 In N-MOmentum biomarker analysis, attack-time sNfL was the strongest predictor of disability worsening at attack and follow-up; attack-time cut-off 32 pg/mL predicted post-attack disability worsening with AUC 0.71 (95% CI 0.51–0.89; P=0.02). At randomized-period end, fewer inebilizumab-treated than placebo-treated participants had sNfL >16 pg/mL: 22% vs 45%; OR 0.36 (95% CI 0.17–0.76; P=0.004). (aktas2023serumneurofilamentlight pages 7-8, aktas2023serumneurofilamentlight pages 1-2)
Biomarker cutoffs Aktas et al. (2023) Journal of Neurology, Neurosurgery & Psychiatry https://doi.org/10.1136/jnnp-2022-330412 Prespecified elevated serum biomarker thresholds: sGFAP >170 pg/mL and sNfL >16 pg/mL (>2 SD above healthy donors). Elevated baseline prevalence in AQP4+ participants: ~30% for sGFAP and 37% for sNfL. Among 198 AQP4+ participants there were 32 adjudicated attacks; 20 had >2-fold increase in sGFAP, 12 had >2-fold change in sNfL. sNfL remained elevated >7 days after attack onset whereas sGFAP returned toward baseline faster. (aktas2023serumneurofilamentlight pages 2-3, aktas2023serumneurofilamentlight pages 4-5)
GFAP effect size Shaygannejad et al. (2024) Medicina https://doi.org/10.3390/medicina60071050 Systematic review/meta-analysis: serum GFAP in NMOSD vs healthy controls showed pooled SMD 0.90 (95% CI 0.73–1.07; P<0.001; I²=10%), supporting GFAP as an astrocytopathy-linked biomarker. (shaygannejad2024theroleof pages 1-2)
Biomarker overview Rodin & Chitnis (2024) Frontiers in Neurology https://doi.org/10.3389/fneur.2024.1415535 Review summary: sGFAP commonly rises ~4–20× above recent baseline within <1 week of attack and higher baseline sGFAP predicts shorter time to next attack (reported hazard ratios ~3–11 across studies). sNfL declines more slowly and may remain elevated for months to years; AQP4-IgG is diagnostically useful but not reliable for monitoring activity or treatment response. (rodin2024solublebiomarkersfor pages 1-2)

Table: This table compiles high-yield NMOSD evidence from retrieved sources, covering diagnostic criteria, epidemiology, major therapies, and biomarker findings with quantitative results, journals, URLs, and citations.

1. Disease information

1.1 Overview (what is the disease?)

NMOSD is defined clinically by inflammatory demyelinating attacks involving the optic nerve, spinal cord, and additional CNS regions (e.g., area postrema/dorsal medulla, brainstem, diencephalon, cerebrum). The IPND 2015 consensus emphasizes integrating clinical, serologic, and neuroimaging data, and explicitly states that diagnosis is not based on AQP4-IgG alone. (wingerchuk2015internationalconsensusdiagnostic pages 2-3)

1.2 Key identifiers and ontology cross-references

  • Consensus definition / diagnostic anchor: International Panel for NMO Diagnosis (IPND) 2015 criteria (Neurology, July 2015) (wingerchuk2015internationalconsensusdiagnostic pages 3-3)
  • MONDO / OMIM / Orphanet / ICD-10 / ICD-11 / MeSH: Not retrievable from the current tool context; therefore not asserted here.

1.3 Common synonyms / alternative names

  • “Neuromyelitis optica” (NMO) is described as a related/preceding term unified under “NMOSD” in the IPND 2015 nomenclature. (wingerchuk2015internationalconsensusdiagnostic pages 2-3)

1.4 Evidence source type

The report integrates: * Aggregated disease-level resources: IPND consensus criteria (wingerchuk2015internationalconsensusdiagnostic pages 3-3) * Real-world aggregated EHR data: U.S. prevalence analysis using TriNetX network (briggs2024prevalenceofneuromyelitis pages 1-3) * Randomized controlled trials and trial-derived biomarker analyses: PREVENT (eculizumab), SAkuraStar (satralizumab), N-MOmentum biomarker analyses, CHAMPION-NMOSD interim (ravulizumab). (pittock2019eculizumabinaquaporin4–positive pages 4-5, traboulsee2020safetyandefficacy pages 1-2, aktas2023serumneurofilamentlight pages 2-3, pittock2024p.011efficacyand pages 1-1) * Post-marketing surveillance: Japan eculizumab all-case surveillance. (nakashima2023longtermsafetyand pages 1-2)

2. Etiology

2.1 Primary causal factors (current understanding)

AQP4-IgG–positive NMOSD is widely conceptualized as an antibody-mediated autoimmune astrocytopathy in which AQP4-IgG targets AQP4 on astrocytic endfeet, triggering downstream complement activation and cellular cytotoxicity mechanisms leading to tissue injury. (thangaleela2023neuromyelitisopticaspectrum pages 1-2)

2.2 Risk factors

Demographic risk patterns

A large U.S. EHR-based prevalence analysis (2022 prevalence estimate; publication Jan 2024) reported clear sex and race differences: overall prevalence 6.88/100,000, higher in females (9.48/100,000) than males (3.52/100,000), and highest in Black individuals (12.99/100,000) followed by Asian individuals (9.41/100,000) and White individuals (5.58/100,000). (briggs2024prevalenceofneuromyelitis pages 1-3, briggs2024prevalenceofneuromyelitis media c3f20c73)

Infectious / microbiome-associated triggers and gene–environment hypotheses

A 2024 review of gut microbiota in NMOSD reported that 20–30% of recurrent NMOSD cases have preceding infections and described molecular mimicry evidence involving Clostridium perfringens: AQP4-specific T-cell epitopes have ~90% homology to bacterial peptide sequences (ABC-TP), and patient Th17 cells proliferate in response to the corresponding bacterial peptide, supporting cross-reactivity as a plausible trigger/amplifier of AQP4-targeted immunity. (yao2024theroleof pages 5-6, yao2024theroleof pages 6-8)

Genetic susceptibility (examples from recent review synthesis)

A 2023 review summarized HLA associations reported across populations (e.g., HLA-DRB103; HLA-DRB105:01; DRB1*1602) and additional immune-gene polymorphism signals (e.g., IL-17 gene polymorphism; PD-1 receptor polymorphism), noting population specificity. (thangaleela2023neuromyelitisopticaspectrum pages 2-4)

2.3 Protective factors

No clearly established protective genetic or environmental factors were retrievable in the current evidence context.

2.4 Gene–environment interactions

The microbiome-driven molecular mimicry hypothesis (AQP4 peptide homology with bacterial antigens and Th17 cross-reactivity) is a concrete gene–environment interaction model: genetic susceptibility shaping adaptive immune responses, while environmental microbial exposures provide cross-reactive epitopes and inflammatory milieu. (yao2024theroleof pages 6-8)

3. Phenotypes

3.1 Core clinical phenotypes and suggested HPO terms

The IPND 2015 diagnostic framework defines six core clinical characteristics (phenotype anchors) (bennett2016findingnmothe pages 11-12, wingerchuk2015internationalconsensusdiagnostic pages 3-3): 1. Optic neuritis — suggested HPO: Optic neuritis (HP:0001088) 2. Acute myelitis — suggested HPO: Myelitis (HP:0002380); and for LETM: Longitudinally extensive transverse myelitis (clinical descriptor; HPO mapping may be represented by spinal cord inflammatory lesion terms) 3. Area postrema syndrome (“hiccups; nausea and vomiting”) — suggested HPO: Intractable hiccups (HP:0010817), Nausea (HP:0002018), Vomiting (HP:0002013) 4. Acute brainstem syndrome — suggested HPO: Brainstem dysfunction (HP:0002363) 5. Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions — suggested HPO: Narcolepsy (HP:0002526) 6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions — suggested HPO: Seizure (HP:0001250) and broader cerebral dysfunction terms depending on presentation

3.2 Phenotype characteristics (onset/course)

NMOSD is typically episodic/relapsing, and relapse prevention is emphasized because single attacks can cause severe and irreversible disability. CHAMPION-NMOSD interim data support disability stability (91.4% without clinically important EDSS worsening), consistent with effective relapse prevention in treated cohorts. (pittock2024p.011efficacyand pages 1-1)

3.3 Laboratory and imaging-related phenotypes

For AQP4-IgG seronegative or unknown cases, IPND 2015 requires additional MRI features tailored to the clinical syndrome (e.g., LETM ≥3 contiguous vertebral segments; dorsal medulla/area postrema lesions; periependymal brainstem lesions). (wingerchuk2015internationalconsensusdiagnostic pages 3-4)

3.4 Quality-of-life impact

Validated QoL instrument statistics (e.g., EQ-5D, SF-36) were not retrievable in the current evidence context. However, the disease burden is implied by attack-related disability risks and the emphasis on relapse prevention to avoid irreversible impairment. (rodin2024solublebiomarkersfor pages 1-2)

4. Genetic / molecular information

4.1 Causal genes

NMOSD is not a monogenic disorder in the retrieved evidence. Instead, it is primarily an autoimmune disease defined by pathogenic autoantibodies (AQP4-IgG) and associated immunogenetic susceptibility signals. (thangaleela2023neuromyelitisopticaspectrum pages 2-4)

4.2 Key molecular targets and biomarkers

  • AQP4 (aquaporin-4): main autoantigen in a large fraction of NMOSD, forming the basis for AQP4-IgG serologic stratification. (wingerchuk2015internationalconsensusdiagnostic pages 3-3)
  • Complement C5: therapeutic target for eculizumab and ravulizumab (terminal complement inhibition). (ortiz2024immediateandsustained pages 1-2, pittock2019eculizumabinaquaporin4–positive pages 4-5)
  • IL-6 receptor: therapeutic target for satralizumab. (traboulsee2020safetyandefficacy pages 1-2)

4.3 Epigenetics / chromosomal abnormalities

Not retrievable from current context.

5. Environmental information

5.1 Infectious agents and microbiome-related exposures

The microbiome literature implicated Clostridium perfringens enrichment and proposed molecular mimicry and toxin-mediated mechanisms (epsilon toxin crossing BBB and damaging CNS cells). (yao2024theroleof pages 6-8)

5.2 Lifestyle factors

Not supported with specific quantitative evidence in the retrieved context.

6. Mechanism / pathophysiology

6.1 Causal chain (AQP4-IgG+ NMOSD)

A mechanistic summary supported by recent reviews: 1. Peripheral AQP4-IgG (and AQP4-reactive T/B cell responses) exist systemically. 2. CNS access occurs during blood–brain barrier (BBB) dysfunction, enabling AQP4-IgG to reach astrocytic endfeet. 3. Binding of AQP4-IgG to AQP4 triggers astrocyte injury via complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). 4. Complement activation culminates in membrane attack complex (MAC) formation and inflammatory recruitment. 5. Downstream consequences include astrocyte loss (GFAP changes), demyelination, and neuronal injury, producing clinical attacks. (thangaleela2023neuromyelitisopticaspectrum pages 1-2, xu2025aquaporin4iggseropositiveneuromyelitisoptica pages 1-2)

6.2 Key pathways (suggested GO terms)

  • Complement activation, classical pathway (GO:0006958)
  • Antibody-mediated complement activation (GO:0002560)
  • Antibody-dependent cellular cytotoxicity (GO:0001788)
  • Inflammatory response (GO:0006954)
  • Blood–brain barrier disruption / regulation of BBB permeability (conceptual; GO terms may include regulation of endothelial barrier function)

6.3 Cell types involved (suggested CL terms)

  • Astrocyte (CL:0000127)
  • Microglial cell (CL:0000129)
  • Macrophage (CL:0000235)
  • Neutrophil (CL:0000775)
  • B cell / plasmablast (B cell CL:0000236; plasmablast CL:0000980)

6.4 Anatomical localization (suggested UBERON)

  • Optic nerve (UBERON:0001890)
  • Spinal cord (UBERON:0002240)
  • Area postrema (dorsal medulla) (UBERON:0001937)
  • Brainstem (UBERON:0002298)
  • Diencephalon (UBERON:0001896)

6.5 Distinction from MOG antibody-associated disease (MOGAD)

A 2023 pathology review emphasizes that MOGAD pathology is principally inflammatory demyelination without astrocyte destruction, contrasting with AQP4-positive NMOSD where complement deposition and astrocyte-targeted injury are central concepts. (pittock2024p.011efficacyand pages 1-1)

7. Anatomical structures affected

Primary: optic nerves and spinal cord; additional CNS regions as per IPND core characteristics (area postrema/dorsal medulla, brainstem, diencephalon, cerebrum). (bennett2016findingnmothe pages 11-12)

8. Temporal development

NMOSD is commonly relapsing with discrete attacks; IPND criteria require at least one clinical attack and note that asymptomatic AQP4-IgG positivity is insufficient for diagnosis. (wingerchuk2015internationalconsensusdiagnostic pages 3-3)

9. Inheritance and population

9.1 Epidemiology (recent statistics)

A U.S. 2022 prevalence estimate using a large aggregated EHR network (TriNetX; 55 healthcare organizations; 25.7 million patients) found 6.88/100,000 prevalence overall with marked sex/race differences and an estimated ~22,000 Americans living with NMOSD in 2022. (briggs2024prevalenceofneuromyelitis pages 1-3, briggs2024prevalenceofneuromyelitis media c3f20c73, briggs2024prevalenceofneuromyelitis media be629dae)

9.2 Inheritance

No Mendelian inheritance pattern is supported by retrieved evidence; disease is best described as multifactorial autoimmune with immunogenetic susceptibility signals. (thangaleela2023neuromyelitisopticaspectrum pages 2-4)

10. Diagnostics

10.1 Clinical diagnostic criteria (IPND 2015)

The IPND 2015 criteria define NMOSD and stratify diagnosis by AQP4-IgG status: * NMOSD with AQP4-IgG: (1) ≥1 core clinical characteristic; (2) positive AQP4-IgG using best available method; (3) exclusion of alternative diagnoses. (bennett2016findingnmothe pages 11-12, wingerchuk2015internationalconsensusdiagnostic pages 3-3) * NMOSD without AQP4-IgG (or unknown): ≥2 core clinical characteristics from ≥1 attacks, requiring dissemination in space and additional MRI requirements, with at least one of optic neuritis, acute myelitis with LETM, or area postrema syndrome. (bennett2016findingnmothe pages 11-12, wingerchuk2015internationalconsensusdiagnostic pages 3-3)

10.2 Laboratory testing

AQP4-IgG testing is central, and cell-based assays are recommended as best-available detection methods. (wingerchuk2015internationalconsensusdiagnostic pages 3-3, bennett2016findingnmothe pages 3-4)

10.3 Differential diagnosis (examples)

NMOSD is differentiated from multiple sclerosis and other inflammatory myelopathies using clinical pattern plus MRI requirements (e.g., LETM, area postrema lesions) and supportive CSF features; oligoclonal bands can be absent in a large fraction of cases, which can be helpful in differentiation. (baranello2015neuromyelitisopticaspectrum pages 5-5, wingerchuk2015internationalconsensusdiagnostic pages 3-4)

11. Outcome / prognosis

Relapse prevention strongly influences prognosis. In CHAMPION-NMOSD interim data, no adjudicated on-trial relapses were observed and disability measures were stable for most patients over a median follow-up of 138.4 weeks. (pittock2024p.011efficacyand pages 1-1)

12. Treatment

12.1 Acute attack management (contextual)

Acute attacks are commonly managed with high-dose corticosteroids and escalation strategies such as apheresis (plasmapheresis) per historical standards; specific quantitative acute-therapy outcomes were not retrieved in this context. (baranello2015neuromyelitisopticaspectrum pages 5-5)

12.2 Maintenance relapse-prevention therapies (targeted biologics)

Complement C5 inhibitors

  • Eculizumab (PREVENT; NEJM; Aug 2019): Adjudicated relapses occurred in 3/96 (3%) eculizumab vs 20/47 (43%) placebo; hazard ratio 0.06 (95% CI 0.02–0.20; P<0.001); ARR 0.02 vs 0.35. (pittock2019eculizumabinaquaporin4–positive pages 4-5)
  • Eculizumab real-world (Japan PMS; Jan 2023): relapse rate fell from 0.74/patient-year (pre-treatment) to 0.02/patient-year after initiation; no meningococcal infections in interim analysis; steroid-sparing observed (prednisolone >10 mg/day dropped to 0% by 100–104 weeks). (nakashima2023longtermsafetyand pages 1-2)
  • Ravulizumab (CHAMPION-NMOSD interim; May 2024 abstract): 0 adjudicated on-trial relapses in 58 patients across primary period + extension; TEAEs 94.8% and serious AEs 25.9%. (pittock2024p.011efficacyand pages 1-1)

IL-6 receptor blockade

  • Satralizumab monotherapy (SAkuraStar; Lancet Neurology; May 2020): protocol-defined relapses in 19/63 (30%) satralizumab vs 16/32 (50%) placebo; hazard ratio 0.45 (95% CI 0.23–0.89; p=0.018). (traboulsee2020safetyandefficacy pages 1-2)
  • A secondary summary source reports AQP4-IgG+ subgroup hazard ratio 0.26 (0.11–0.63) (74% risk reduction). (duchow2021satralizumabinthe pages 4-5)

B-cell depletion targeting CD19

While the pivotal inebilizumab trial statistics were not directly retrievable here, trial-derived biomarker analyses demonstrate biologic effect on damage markers and suggest potential utility for stratifying relapse severity and recovery: * Inebilizumab was associated with lower sNfL and sGFAP versus placebo in N-MOmentum biomarker analysis. (aktas2023serumneurofilamentlight pages 1-2)

12.3 Biomarkers for monitoring treatment and risk

From a 2023 biomarker analysis (JN Neurol Neurosurg Psychiatry) linked to N-MOmentum: * Attack-time sNfL cut-off 32 pg/mL predicted disability worsening after attacks (AUC 0.71). (aktas2023serumneurofilamentlight pages 1-2) * Prespecified “elevated” thresholds: sGFAP >170 pg/mL and sNfL >16 pg/mL (>2 SD above healthy donors). (aktas2023serumneurofilamentlight pages 2-3)

12.4 MAXO suggestions (examples)

  • Complement inhibition therapy (MAXO concept: complement inhibitor administration) — eculizumab/ravulizumab (pittock2019eculizumabinaquaporin4–positive pages 4-5, pittock2024p.011efficacyand pages 1-1)
  • Interleukin-6 receptor antagonist therapy — satralizumab (traboulsee2020safetyandefficacy pages 1-2)
  • B cell depletion therapy — inebilizumab (aktas2023serumneurofilamentlight pages 1-2)
  • Plasma exchange therapy — for acute attack escalation (historical standard; not quantitatively evidenced here) (baranello2015neuromyelitisopticaspectrum pages 5-5)

12.5 Current applications / real-world implementation

Post-marketing surveillance in Japan demonstrates real-world deployment of eculizumab, including relapse-rate reduction, monitoring for adverse drug reactions, and steroid-sparing trajectories. (nakashima2023longtermsafetyand pages 1-2)

13. Prevention

Primary prevention of NMOSD onset is not established. Practical prevention is predominantly secondary/tertiary prevention of relapses and disability via long-term immunotherapy, supported by phase 3 trial evidence and real-world surveillance (e.g., eculizumab PMS). (nakashima2023longtermsafetyand pages 1-2, pittock2019eculizumabinaquaporin4–positive pages 4-5)

Vaccination- and pregnancy-specific prevention guidance was not retrievable in the current context.

14. Other species / natural disease

Not established in the retrieved evidence context.

15. Model organisms

Experimental systems are largely built on AQP4-IgG pathogenesis: * Rodent passive-transfer models: AQP4-IgG introduction often requires BBB disruption or co-administration of human complement (mice) to recapitulate complement-mediated pathology; rats can develop more NMOSD-like lesions with intact complement. Peripheral administration frequently leads to antibody sequestration in AQP4-expressing peripheral organs rather than CNS deposition unless BBB is breached. (huang2024scientificissueswith pages 1-3) * In vitro/ex vivo models: astrocyte and slice models recapitulate AQP4 loss, astrocytopathy, complement activation, demyelination, and neuronal loss, supporting mechanistic studies and therapeutic screening, but they do not fully capture the human disease process. (xu2025aquaporin4iggseropositiveneuromyelitisoptica pages 1-2)

Recent developments and expert analysis (2023–2024)

  1. Epidemiology update (2024): Large-scale EHR data indicate ~22,000 Americans living with NMOSD in 2022 and highlight substantial race/sex disparities, with the highest prevalence in Black individuals and a strong female predominance. (briggs2024prevalenceofneuromyelitis pages 1-3, briggs2024prevalenceofneuromyelitis media c3f20c73)
  2. Biomarker maturation (2023–2024): Attack-linked serum biomarkers (GFAP and NfL) show different kinetics and prognostic implications; sNfL at attack predicts post-attack disability worsening and is mitigated by inebilizumab, while sGFAP is tightly linked to astrocytic injury and is elevated in NMOSD vs controls (SMD 0.9). (aktas2023serumneurofilamentlight pages 1-2, shaygannejad2024theroleof pages 1-2)
  3. Expansion of targeted relapse prevention (2024): Ravulizumab (long-acting C5 inhibitor) shows sustained terminal complement inhibition pharmacodynamically and interim clinical data with no adjudicated on-trial relapses in CHAMPION-NMOSD. (ortiz2024immediateandsustained pages 1-2, pittock2024p.011efficacyand pages 1-1)

Limitations of this report (evidence gaps)

  • Formal ontology identifiers (MONDO, MeSH, Orphanet, ICD-10/ICD-11) were not retrievable via the current tool context.
  • QoL instrument outcomes (EQ-5D/SF-36/PROMIS) were not available in retrieved primary evidence.
  • Direct inebilizumab pivotal relapse-prevention effect sizes were not retrieved (only biomarker analyses and secondary summaries).

URLs and publication dates (examples of key sources used)

  • Wingerchuk et al., Neurology (July 2015): https://doi.org/10.1212/WNL.0000000000001729 (wingerchuk2015internationalconsensusdiagnostic pages 3-3)
  • Briggs & Shaia, Multiple Sclerosis Journal (Jan 2024): https://doi.org/10.1177/13524585231224683 (briggs2024prevalenceofneuromyelitis pages 1-3)
  • Pittock et al., NEJM (Aug 2019): https://doi.org/10.1056/NEJMoa1900866 (pittock2019eculizumabinaquaporin4–positive pages 4-5)
  • Nakashima et al., Therapeutic Advances in Neurological Disorders (Jan 2023): https://doi.org/10.1177/17562864231181177 (nakashima2023longtermsafetyand pages 1-2)
  • Ortiz et al., Frontiers in Neurology (Jan 2024): https://doi.org/10.3389/fneur.2024.1332890 (ortiz2024immediateandsustained pages 1-2)
  • Pittock et al., Canadian Journal of Neurological Sciences (May 2024): https://doi.org/10.1017/cjn.2024.119 (pittock2024p.011efficacyand pages 1-1)
  • Aktas et al., JNNP (May 2023): https://doi.org/10.1136/jnnp-2022-330412 (aktas2023serumneurofilamentlight pages 1-2)
  • Rodin & Chitnis, Frontiers in Neurology (May 2024): https://doi.org/10.3389/fneur.2024.1415535 (rodin2024solublebiomarkersfor pages 1-2)

References

  1. (wingerchuk2015internationalconsensusdiagnostic pages 3-3): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik, and Brian G. Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85:177-189, Jul 2015. URL: https://doi.org/10.1212/wnl.0000000000001729, doi:10.1212/wnl.0000000000001729. This article has 5307 citations and is from a highest quality peer-reviewed journal.

  2. (rodin2024solublebiomarkersfor pages 1-2): Rachel E. Rodin and Tanuja Chitnis. Soluble biomarkers for neuromyelitis optica spectrum disorders: a mini review. Frontiers in Neurology, May 2024. URL: https://doi.org/10.3389/fneur.2024.1415535, doi:10.3389/fneur.2024.1415535. This article has 17 citations and is from a peer-reviewed journal.

  3. (bennett2016findingnmothe pages 11-12): Jeffrey L. Bennett. Finding nmo: the evolving diagnostic criteria of neuromyelitis optica. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 36 3:238-45, Sep 2016. URL: https://doi.org/10.1097/wno.0000000000000396, doi:10.1097/wno.0000000000000396. This article has 57 citations.

  4. (wingerchuk2015internationalconsensusdiagnostic pages 2-3): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik, and Brian G. Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85:177-189, Jul 2015. URL: https://doi.org/10.1212/wnl.0000000000001729, doi:10.1212/wnl.0000000000001729. This article has 5307 citations and is from a highest quality peer-reviewed journal.

  5. (briggs2024prevalenceofneuromyelitis pages 1-3): Farren B S Briggs and Jacqueline Shaia. Prevalence of neuromyelitis optica spectrum disorder in the united states. Multiple Sclerosis Journal, 30:316-324, Jan 2024. URL: https://doi.org/10.1177/13524585231224683, doi:10.1177/13524585231224683. This article has 25 citations.

  6. (briggs2024prevalenceofneuromyelitis media c3f20c73): Farren B S Briggs and Jacqueline Shaia. Prevalence of neuromyelitis optica spectrum disorder in the united states. Multiple Sclerosis Journal, 30:316-324, Jan 2024. URL: https://doi.org/10.1177/13524585231224683, doi:10.1177/13524585231224683. This article has 25 citations.

  7. (pittock2019eculizumabinaquaporin4–positive pages 4-5): Sean J. Pittock, Achim Berthele, Kazuo Fujihara, Ho Jin Kim, Michael Levy, Jacqueline Palace, Ichiro Nakashima, Murat Terzi, Natalia Totolyan, Shanthi Viswanathan, Kai-Chen Wang, Amy Pace, Kenji P. Fujita, Róisín Armstrong, and Dean M. Wingerchuk. Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder. New England Journal of Medicine, 381:614-625, Aug 2019. URL: https://doi.org/10.1056/nejmoa1900866, doi:10.1056/nejmoa1900866. This article has 948 citations and is from a highest quality peer-reviewed journal.

  8. (nakashima2023longtermsafetyand pages 1-2): Ichiro Nakashima, Jin Nakahara, Hiroaki Yokote, Yasuhiro Manabe, Kazumi Okamura, Kou Hasegawa, and Kazuo Fujihara. Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in japan. Therapeutic Advances in Neurological Disorders, Jan 2023. URL: https://doi.org/10.1177/17562864231181177, doi:10.1177/17562864231181177. This article has 28 citations and is from a peer-reviewed journal.

  9. (pittock2024p.011efficacyand pages 1-1): SJ Pittock, M Barnett, JL Bennett, A Berthele, J de Sèze, M Levy, I Nakashima, C Oreja-Guevara, J Palace, F Paul, C Pozzilli, Y Mashhoon, K Allen, B Parks, H Kim, and G Vorobeychik. P.011 efficacy and safety of ravulizumab in adults with aqp4+ nmosd: interim analysis from the ongoing phase 3 champion-nmosd trial. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 51:S17-S17, May 2024. URL: https://doi.org/10.1017/cjn.2024.119, doi:10.1017/cjn.2024.119. This article has 0 citations.

  10. (ortiz2024immediateandsustained pages 1-2): Stephan Ortiz, Sean J. Pittock, Achim Berthele, Michael Levy, Ichiro Nakashima, Celia Oreja-Guevara, Kerstin Allen, Yasmin Mashhoon, Becky Parks, and Ho Jin Kim. Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Frontiers in Neurology, Jan 2024. URL: https://doi.org/10.3389/fneur.2024.1332890, doi:10.3389/fneur.2024.1332890. This article has 10 citations and is from a peer-reviewed journal.

  11. (aktas2023serumneurofilamentlight pages 7-8): Orhan Aktas, Hans-Peter Hartung, Michael A Smith, William A Rees, Kazuo Fujihara, Friedemann Paul, Romain Marignier, Jeffrey L Bennett, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Dean M Wingerchuk, Gary Cutter, Dewei She, Michele Gunsior, Daniel Cimbora, Eliezer Katz, and Bruce A Cree. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery & Psychiatry, 94:757-768, May 2023. URL: https://doi.org/10.1136/jnnp-2022-330412, doi:10.1136/jnnp-2022-330412. This article has 43 citations.

  12. (aktas2023serumneurofilamentlight pages 1-2): Orhan Aktas, Hans-Peter Hartung, Michael A Smith, William A Rees, Kazuo Fujihara, Friedemann Paul, Romain Marignier, Jeffrey L Bennett, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Dean M Wingerchuk, Gary Cutter, Dewei She, Michele Gunsior, Daniel Cimbora, Eliezer Katz, and Bruce A Cree. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery & Psychiatry, 94:757-768, May 2023. URL: https://doi.org/10.1136/jnnp-2022-330412, doi:10.1136/jnnp-2022-330412. This article has 43 citations.

  13. (aktas2023serumneurofilamentlight pages 2-3): Orhan Aktas, Hans-Peter Hartung, Michael A Smith, William A Rees, Kazuo Fujihara, Friedemann Paul, Romain Marignier, Jeffrey L Bennett, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Dean M Wingerchuk, Gary Cutter, Dewei She, Michele Gunsior, Daniel Cimbora, Eliezer Katz, and Bruce A Cree. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery & Psychiatry, 94:757-768, May 2023. URL: https://doi.org/10.1136/jnnp-2022-330412, doi:10.1136/jnnp-2022-330412. This article has 43 citations.

  14. (aktas2023serumneurofilamentlight pages 4-5): Orhan Aktas, Hans-Peter Hartung, Michael A Smith, William A Rees, Kazuo Fujihara, Friedemann Paul, Romain Marignier, Jeffrey L Bennett, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Dean M Wingerchuk, Gary Cutter, Dewei She, Michele Gunsior, Daniel Cimbora, Eliezer Katz, and Bruce A Cree. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery & Psychiatry, 94:757-768, May 2023. URL: https://doi.org/10.1136/jnnp-2022-330412, doi:10.1136/jnnp-2022-330412. This article has 43 citations.

  15. (shaygannejad2024theroleof pages 1-2): Aysa Shaygannejad, Nazanin Rafiei, Saeed Vaheb, Mohammad Yazdan Panah, Vahid Shaygannejad, and Omid Mirmosayyeb. The role of glial fibrillary acidic protein as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Medicina, 60:1050, Jun 2024. URL: https://doi.org/10.3390/medicina60071050, doi:10.3390/medicina60071050. This article has 17 citations.

  16. (traboulsee2020safetyandefficacy pages 1-2): Anthony Traboulsee, Benjamin M Greenberg, Jeffrey L Bennett, Lech Szczechowski, Edward Fox, Svitlana Shkrobot, Takashi Yamamura, Yusuke Terada, Yuichi Kawata, Padraig Wright, Athos Gianella-Borradori, Hideki Garren, and Brian G Weinshenker. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. The Lancet Neurology, 19:402-412, May 2020. URL: https://doi.org/10.1016/s1474-4422(20)30078-8, doi:10.1016/s1474-4422(20)30078-8. This article has 578 citations and is from a highest quality peer-reviewed journal.

  17. (thangaleela2023neuromyelitisopticaspectrum pages 1-2): Subramanian Thangaleela, Bhagavathi Sundaram Sivamaruthi, Arumugam Radha, Periyanaina Kesika, and Chaiyavat Chaiyasut. Neuromyelitis optica spectrum disorders: clinical perspectives, molecular mechanisms, and treatments. Applied Sciences, 13:5029, Apr 2023. URL: https://doi.org/10.3390/app13085029, doi:10.3390/app13085029. This article has 10 citations.

  18. (yao2024theroleof pages 5-6): Shi-Qi Yao, Xiayin Yang, Ling-Ping Cen, and Shaoying Tan. The role of gut microbiota in neuromyelitis optica spectrum disorder. International Journal of Molecular Sciences, 25:3179, Mar 2024. URL: https://doi.org/10.3390/ijms25063179, doi:10.3390/ijms25063179. This article has 13 citations.

  19. (yao2024theroleof pages 6-8): Shi-Qi Yao, Xiayin Yang, Ling-Ping Cen, and Shaoying Tan. The role of gut microbiota in neuromyelitis optica spectrum disorder. International Journal of Molecular Sciences, 25:3179, Mar 2024. URL: https://doi.org/10.3390/ijms25063179, doi:10.3390/ijms25063179. This article has 13 citations.

  20. (thangaleela2023neuromyelitisopticaspectrum pages 2-4): Subramanian Thangaleela, Bhagavathi Sundaram Sivamaruthi, Arumugam Radha, Periyanaina Kesika, and Chaiyavat Chaiyasut. Neuromyelitis optica spectrum disorders: clinical perspectives, molecular mechanisms, and treatments. Applied Sciences, 13:5029, Apr 2023. URL: https://doi.org/10.3390/app13085029, doi:10.3390/app13085029. This article has 10 citations.

  21. (wingerchuk2015internationalconsensusdiagnostic pages 3-4): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik, and Brian G. Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85:177-189, Jul 2015. URL: https://doi.org/10.1212/wnl.0000000000001729, doi:10.1212/wnl.0000000000001729. This article has 5307 citations and is from a highest quality peer-reviewed journal.

  22. (xu2025aquaporin4iggseropositiveneuromyelitisoptica pages 1-2): Li Xu, Huiming Xu, and Changyong Tang. Aquaporin-4-igg-seropositive neuromyelitis optica spectrum disorders: progress of experimental models based on disease pathogenesis. Neural Regeneration Research, 20:354-365, Jan 2024. URL: https://doi.org/10.4103/nrr.nrr-d-23-01325, doi:10.4103/nrr.nrr-d-23-01325. This article has 15 citations and is from a peer-reviewed journal.

  23. (briggs2024prevalenceofneuromyelitis media be629dae): Farren B S Briggs and Jacqueline Shaia. Prevalence of neuromyelitis optica spectrum disorder in the united states. Multiple Sclerosis Journal, 30:316-324, Jan 2024. URL: https://doi.org/10.1177/13524585231224683, doi:10.1177/13524585231224683. This article has 25 citations.

  24. (bennett2016findingnmothe pages 3-4): Jeffrey L. Bennett. Finding nmo: the evolving diagnostic criteria of neuromyelitis optica. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 36 3:238-45, Sep 2016. URL: https://doi.org/10.1097/wno.0000000000000396, doi:10.1097/wno.0000000000000396. This article has 57 citations.

  25. (baranello2015neuromyelitisopticaspectrum pages 5-5): RJ Baranello and JR Avasarala. Neuromyelitis optica spectrum disorders with and without aquaporin 4 antibody: characterization, differential diagnosis, and recent advances. Journal of Neurology and Therapeutics, 1:9-14, Nov 2015. URL: https://doi.org/10.14312/2397-1304.2015-2, doi:10.14312/2397-1304.2015-2. This article has 98 citations.

  26. (duchow2021satralizumabinthe pages 4-5): Ankelien Duchow and Judith Bellmann-Strobl. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegenerative disease management, 11:49-59, Nov 2021. URL: https://doi.org/10.2217/nmt-2020-0046, doi:10.2217/nmt-2020-0046. This article has 22 citations and is from a peer-reviewed journal.

  27. (huang2024scientificissueswith pages 1-3): Yusen Huang, Tian-wei Wang, Fangruyue Wang, Yujing Wu, Jia Ai, Ying Zhang, Meiyan Shao, and Le Fang. Scientific issues with rodent models of neuromyelitis optic spectrum disorders. Frontiers in Immunology, Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1423107, doi:10.3389/fimmu.2024.1423107. This article has 2 citations and is from a peer-reviewed journal.